跳至主要内容
临床试验/NL-OMON37239
NL-OMON37239撤回不适用

Acute cardiometabolic risks during treatment with haloperidol in elderly patients. - CMH- study

Tergooiziekenhuizen Hilversum0 个研究点目标入组 128 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age 70 years and older
  • - Admission on the department of Orthopedics or Surgery for hip fracture or other fall-related-fractures
  • - Exclusion within 24 hours after admission on the department
  • - The patient or representative speaks either Dutch or English
  • - Patient or representative must be able to give informed consent

排除标准

  • - Use of an antipsychotic agent within 90 days before hospital admission
  • - Start or dose changes in anticoagulant drugs, drugs related to QTc-prolongation, antidiabetic, antihypertensive or cholesterol lowering drugs in the 14 days before admission
  • Additional for subgroup 1:
  • - History of a pacemaker implantation, atrial fibrillation, bundle branch block, congenital Qt- syndrome
  • - Use of QT prolongating drugs (Cert list 1 www.azcert.org) in the 14 days before admission

研究者

发起方
Tergooiziekenhuizen Hilversum

相似试验